From: Emma Ingleby **On Behalf Of** Imti Choonara
Sent: Thursday, November 15, 2012 3:15 PM
To: SANCO PHARMACEUTICALS D5
Subject: PCPD/12/01 - Public Consultation on paediatric report

The European legislation is to be welcomed in that it should improve the evidence basis for the use of medicines.

My main concerns related to whether the European legislation is an improvement on the American system. It was certainly the intention that me-too drugs would not be extensively studied in paediatrics. My question is 'has the Paediatric Committee been successful in ensuring that only appropriate medicines are studied in paediatric patients, i.e. on how many occasions have they made a decision that we only need two or three of a particular group of medicines to be investigated in paediatric patients rather than all the medicinal products that are being developed for adults?'

Imti Choonara
Professor in Child Health
Academic Division of Child Health (University of Nottingham)
The Medical School
Derbyshire Children's Hospital